Michigan is currently home to 2238 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy
NCT05361070
Recruiting
The NSR-GENE study is a longitudinal cohort study of approximately 300 parent-child trios from the Neonatal Seizure Registry and participating site outpatient clinics that aims to evaluate whether and how genes alter the risk of post-neonatal epilepsy among children with acute provoked neonatal seizures. The researchers aim to develop prediction rules to stratify neonates into low, medium, and high risk for post-neonatal epilepsy based on clinical, electroencephalogram (EEG), magnetic resonance... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/02/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhage, Epilepsy, Gene Abnormality
Register for Updates
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
NCT05094089
Recruiting
The SYN 20-01 Study is a non-interventional, prospective, multicenter, multicohort, international, post-market clinical investigation looking into the assessment of GORE® SYNECOR Biomaterial in focused patient populations and in long-term application. Patients with ventral / incisional hernia amenable to hernia mesh repair will be enrolled into two cohorts (US and EU cohort) and followed-up over the period of 60 months.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral
Register for Updates
Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients
NCT06539468
Recruiting
This clinical trial evaluates whether active surveillance (AS) is a safe and comfortable alternative to standard of care (SOC) treatment for elderly patients with low-risk basal cell carcinoma (LR-BCC). Basal cell carcinoma is a type of slow-growing skin cancer that has a very low risk of spreading inside the body (metastasis) or death. Basal cell skin cancers that are smaller across than a nickel in size and located on the trunk or limbs are particularly low risk to overall health. Active surve... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Skin Basal Cell Carcinoma
Register for Updates
The M-Well Inpatient Whole Health Bundle
NCT06405347
Recruiting
This study will utilize a quasi-experimental pre-test/post-test design and will be conducted on the medical and medical/surgical units at the VA Ann Arbor Healthcare System. Hospitalized patients on the intervention units will be offered the Inpatient Whole Health Bundle. This study will evaluate overall satisfaction with the hospital environment and care as well as the bundle and components using a mailed survey of patients discharged from each unit. This study will also conduct a qualitative a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: VA Ann Arbor Healthcare System, Ann Arbor, Michigan
Conditions: Patient Satisfaction
Register for Updates
M-Well Bonding Bundle to Improve Patient-Physician Relationships
NCT06354920
Recruiting
The goal of this clinical trial is to learn more about the interaction between a patient in the hospital and their treating doctor. A good relationship between patients and their doctors can help improve patient care. Doctors will be asked to use strategies to improve their interactions with patients in the hospital. The main questions it aims to answer are: * Will using the intervention strategies improve doctors' empathy towards their patients? * Will using the intervention strategies lead to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Physician-Patient Relations
Register for Updates
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
NCT06247345
Recruiting
This is a Phase Ia/Ib, two-part, randomized, placebo-controlled, double-blinded, first in human(FIH) study to evaluate the safety, tolerability, PK, and PD of ADEL-Y01 in healthy participants in Part 1 and participants with MCI due to AD and mild AD in Part 2. The study includes 2 parts: Part 1 (single ascending dose \[SAD\] and Part 2 (multiple ascending dose \[MAD\]).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/01/2025
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Alzheimer Disease
Register for Updates
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05183126
Recruiting
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Breast Cancer, Metastatic Gastric Cancer, Esophageal Cancer
Register for Updates
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
NCT05164341
Recruiting
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Partial Lipodystrophy
Register for Updates
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
NCT04574856
Recruiting
This study will investigate whether or not intensified radiation therapy adapted during the radiation treatment course to high-risk, treatment-resistant tumor regions will improve overall survival in patients with newly diagnosed glioblastoma (GBM) compared to conventional chemoradiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Glioblastoma
Register for Updates
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT03842696
Recruiting
The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.
Gender:
ALL
Ages:
Between 3 years and 39 years
Trial Updated:
04/01/2025
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Hematologic Diseases, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease, Acute Leukemia in Remission
Register for Updates
Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia
NCT06840470
Recruiting
This study is being completed to determine if 8 weeks of treatment with imiquimod can shrink sebaceous hyperplasia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Sebaceous Hyperplasia
Register for Updates
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
NCT06343298
Recruiting
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/31/2025
Locations: Revival Research Institute, LLC, Dearborn, Michigan
Conditions: Difficult to Control Hypertension
Register for Updates